12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dabrafenib: Phase I/II data

Data from 77 evaluable metastatic melanoma patients with V600 BRAF mutations in the dose-escalation portion of a 3-part Phase I/II trial showed that twice-daily oral dabrafenib plus once-daily oral trametinib produced an ORR of 56%, including 4 complete responses and 39 partial responses, plus 29 cases of stable disease. Median PFS was 8.7 months for twice-daily 75 mg dabrafenib plus once-daily 1 mg trametinib; 8.3 months for twice-daily 150 mg dabrafenib plus once-daily 1 mg trametinib; 5.5 months for twice-daily 150 mg dabrafenib plus once-daily 1.5...

Read the full 410 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >